Anti-Obesity Drugs Including GLP-1 Agonists for PCOS: Systematic Review Informing International Guidelines | Research

The takeaway

Liraglutide and semaglutide appeared superior to placebo for weight-related outcomes in PCOS, but overall evidence remains very limited, with only 11 trials identified to inform the 2023 International PCOS Guideline.

Only 11 trials in the entire literature
Despite PCOS affecting 6-12% of reproductive-age women and its strong link to obesity, systematic review found just 11 trials of anti-obesity agents in PCOS to inform international guidelines

What the researchers found

From 11 trials (545 intervention, 451 control participants, 12 comparisons), most anti-obesity agents improved anthropometric outcomes. Liraglutide, semaglutide, and orlistat appeared superior to placebo. Meta-analysis of exenatide vs metformin found no differences for anthropometric, hyperandrogenism, or metabolic outcomes, except metformin showed slightly lower fasting glucose (MD: 0.10 mmol/L, CI 0.02-0.17, I²=18%). Orlistat + COCP did not improve metabolic outcomes versus COCP alone (fasting insulin MD: -8.65 pmol/L, -33.55 to 16.26, I²=67%). The critical finding is the extreme paucity of evidence for a condition affecting 6-12% of reproductive-age women.

Why it matters

This review directly informed international clinical guidelines for PCOS, the most common endocrine disorder in reproductive-age women. The finding that powerful new drugs like semaglutide have barely been studied in PCOS — despite the condition's strong link to obesity — highlights a major gap in women's health research. It calls for urgent clinical trials of GLP-1 agonists specifically in PCOS populations.

How the study worked

Systematic review and meta-analysis searching Medline, EMBASE, PsycInfo, and CINAHL through July 2022 with a 10-year limit to focus on newer agents. Evaluated efficacy of anti-obesity agents for hormonal, reproductive, metabolic, and psychological outcomes in PCOS. Meta-analyses were possible for only two comparisons due to limited data. Conducted to inform the 2023 International Evidence-based Guideline on PCOS.

What this study cannot tell us

Only 11 trials were identified, severely limiting the evidence. Meta-analysis was possible for only two comparisons. The search had a 10-year limit, potentially missing earlier relevant studies. Most included studies were small. Newer agents (semaglutide, tirzepatide) had minimal representation. Long-term outcomes, fertility effects, and psychological outcomes were inadequately studied. The review's search ended July 2022, predating recent semaglutide expansion.

How to read the evidence

This is a rigorous systematic review and meta-analysis published in Obesity Reviews, conducted specifically to inform the 2023 International Evidence-based Guideline on PCOS. The methodology is strong, but the underlying evidence base is extremely limited.

When this study was published

Published in 2024 with literature through July 2022. This informed the 2023 PCOS guideline update. Given the rapid expansion of GLP-1RA use since then, the evidence gap it identifies is likely being partially addressed by ongoing studies.

The bigger picture

The explosion of GLP-1RA prescribing for obesity creates both an opportunity and a gap for PCOS. Millions of women with PCOS could benefit from these drugs, but the evidence base is remarkably thin. This guideline-informing review exposes the disconnect between the massive commercial success of GLP-1 agonists and the minimal investment in studying them for one of the most common conditions they could address.

Questions still open

Will large-scale randomized trials of semaglutide and tirzepatide specifically in PCOS populations be prioritized by pharmaceutical companies?
How do GLP-1 agonists affect PCOS-specific outcomes like androgen levels, ovulation, and fertility compared to metformin?
Should GLP-1 agonists be recommended for overweight women with PCOS based on limited but promising evidence, or should guidelines wait for stronger data?

Common questions

Why haven't GLP-1 agonists been studied more in PCOS?

PCOS research has historically been underfunded relative to how many women it affects. Additionally, GLP-1 agonists were initially developed for diabetes and later obesity — conditions with larger commercial markets. Women with PCOS who are overweight can often access these drugs off-label, which may reduce the commercial incentive for PCOS-specific trials.

What does this review mean for women with PCOS considering GLP-1 agonists?

The limited evidence available is encouraging — GLP-1 agonists, particularly liraglutide and semaglutide, showed the best results for weight loss in PCOS. However, the review can't definitively say these drugs improve PCOS-specific outcomes like fertility and hormone balance. Women should discuss with their doctor whether the general obesity evidence plus the limited PCOS data supports trying these medications for their individual situation.

Read the original research

Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.

Obesity reviews : an official journal of the International Association for the Study of Obesity, 25(5), e13704

View on PubMed ↗Publisher’s paper ↗

Citation

Goldberg, Alyse; Graca, Sandro; Liu, Jing; Rao, Vibhuti; Witchel, Selma Feldman; Pena, Alexia; Li, Rong; Mousa, Aya; Tay, Chau Thien; Pattuwage, Loyal; Teede, Helena; Yildiz, Bulent O; Ee, Carolyn. (2024). Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.. Obesity reviews : an official journal of the International Association for the Study of Obesity, 25(5), e13704. https://doi.org/10.1111/obr.13704